Altimmune, Inc. announced on October 1, 2025 that Christophe Arbet‑Engels, MD, PhD, will serve as Chief Medical Officer, effective October 1, 2025. The appointment follows the retirement of former CMO Scott Harris, who will remain as Senior Strategic Advisor until February 2026.
Dr. Arbet‑Engels brings more than 30 years of experience in clinical development, having led late‑stage programs at X4 Pharmaceuticals, Neurogastrx, and Poxel Pharmaceuticals, and previously served as CMO at X4 where he helped secure FDA approval of mavorixafor for WHIM syndrome. His expertise spans regulatory approvals, commercial launches, and global product development, positioning him to steer pemvidutide’s Phase 3 program in metabolic dysfunction‑associated steatohepatitis (MASH).
The company emphasized that Dr. Arbet‑Engels’ leadership will be instrumental as pemvidutide advances toward the End‑of‑Phase 2 meeting with the FDA and the planned initiation of the Phase 3 trial in MASH. His appointment is intended to strengthen Altimmune’s clinical development capabilities and accelerate progress toward regulatory approval and commercialization of its lead asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.